Lessons learned about the therapeutic potential of the natural human immune response to lung cancer

Bibliography

• KOHLER G, MILSTEIN C: ontinuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256: 495–497.
   PubMed Web of Science ®Google Scholar
• ••The seminal paper describing the creation of monoclonalantibody technology.
   Google Scholar
• GLASSY MC: Production methods for generating human monoclonal antibodies. Hum. Antibod. Hybridomas (1993) 4:154–165.
   PubMedGoogle Scholar
• HASPEL MV, MCCABE RP, POMOTO N et al.: Generationof tumour cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res. (1985) 45:2490–2496.
   Google Scholar
• MCLAUGHLIN P, WHITE CA, GRILLO-LOPEZ ALMALONEY DG: Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (1998) 12:1763–1769.
   PubMed Web of Science ®Google Scholar
• •Details of an important human antibody and clinical trials.
   Google Scholar
• BASELGA J, NORTON L, ALBANELL J, KIM YM, MENDEL-SOHN J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti tumor activity of paclitaxel and doxorubicin against HER2/neu overex-pressing human breast cancer xenografts. Cancer Res. (1998) 58:2825–2831.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, DONOVAN K, HAMBLIN TJ: Antibody therapy for treatment of multiple myeloma. Sem. Hematol. (1999) 36:30–33.
   PubMed Web of Science ®Google Scholar
• KODA K, GLASSY MC, MCKNIGHT ME et al.: Humanmonoclonal antibody SK-1 immunotarageting for rectal carcinoma. Int. J. Immunother. (1998) 14:153–161.
   Web of Science ®Google Scholar
• •Clinical results from a natural human antibody.
   Google Scholar
• HOLLIGER P, HOOGENBOOM H: Antibodies come back from the brink. Nature Biotechnol. (1998) 16:1015–1016.
   PubMed Web of Science ®Google Scholar
• GLASSY MC, MCKNIGHT ME: A novel drug discovery programme utilizing the human immune response. Curr. Opin. Invest. Drugs (1993) 2: 853–858.
   Google Scholar
• •Seminal paper describing the concepts of drug discovery through the human immune response.
   Google Scholar
• GLASSY MC, MCKNIGHT ME: Pharming the human lymph node. Exp. Opin. Invest. Drugs (1994) 3:1057–1060.
   Google Scholar
• GLASSY MC, MCKNIGHT ME: The rate-limiting step in obtaining human monoclonal antibody drug pharma-ceuticals. Exp. Opin. Invest. Drugs (1995) 4:225–228.
   Google Scholar
• MCKNIGHT ME, GLASSY MC: The autoimmunity of cancer as applied to drug development. Exp. Opin. Invest. Drugs (1995) 4:657–661.
   Google Scholar
• SAITO H, TANIGUCHI M, FUKUSAWA T, YAMAGUCHI Y, FUJISAWA T: Establishment of internal-image anti-idiotype monoclonal antibodies to a human antibody to lung cancer. Cancer Immunol Immunother. (1997) 44:83–87.
   PubMed Web of Science ®Google Scholar
• GLASSY MC: Immortalization of human lymphocytes from a tumor involved lymph node. Cancer Res. (1987) 47:5181–5188.
   PubMed Web of Science ®Google Scholar
• KODAK, GLASSY MC, CHANG HR: Generation of human monoclonal antibodies against colon cancer. Arch. Surg. (1990) 125:1591–1597.
   PubMed Web of Science ®Google Scholar
• CHANG HR, KODAK, CHANG S, BAIRD S: AgSK1, a novel carcinoma associated antigen. Cancer Res. (1993) 53:1122–1127.
   PubMed Web of Science ®Google Scholar
• CHANG HR, KODA K, MCKNIGHT ME, GLASSY MC: Tumor-associated antigens recognized by human monoclonal antibodies. Ann. Surg. Oncol. (1994) 1:213–221.
   PubMed Web of Science ®Google Scholar
• KODA K, NAKAJIMA N, SAITO N, YASUTOMI J, MCKNIGHT ME, GLASSY MC: A human natural antibody to adenocarcinoma that inhibits tumour cell migration. Brit. J. Cancer (1998) 78:1313–1322.
   PubMed Web of Science ®Google Scholar
• SHOJI M, KAWAMOTO S, SATO S etal.: Specific reactivityof human monoclonal antibody AE6F4 against cancer cells in tissues and sputa from lung cancer patients. Hum. Antibod. Hybridomas (1994) 5:116–122.
   Google Scholar
• ICHIKAWA A, TACHIBANA H, KAWAMOTO S et al.: Cytokeratin 8 and 19 as antigens recognized by adenocarcinoma-reactive human monoclonal antibody AE6F4. Hum. Antibod. (1997) 8:195–201.
   PubMedGoogle Scholar
• MUKERJEE S, GLASSY M, MEDENICA R: Characterizationof TB94, a human monoclonal antibody against lung carcinoma. Proc. 9th Int. Congress Immunol (1995):53.
   Google Scholar
• MUKERJEE S, MEDENICA R: eneration and characteri - zation of a human monoclonal antibody against lung carcinoma. Hum. Antibod Hybridoma (1995) 6:3.
   Google Scholar
• YANG XD, JIA XC, CORVALAN JRF, WANG P, DAVIS CG, JAKOBOVITS A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. (1999) 59:1236–1243.
   PubMed Web of Science ®Google Scholar
• ••This paper describes the usefulness of the xenomousetechnology.
   Google Scholar
• MUKERJEE S, NASOFF M, MCKNIGHT M, GLASSY MC: Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells. Hybridoma (1998) 17:133–142.
   PubMed Web of Science ®Google Scholar
• MUKERJEE S, MCKNIGHT ME, GLASSY MC: Immuno-screening protocols for the identification of clinically useful antibodies and antigens. Exp. Opin. Invest. Drugs (1998) 7:373–389.
   PubMedGoogle Scholar
• AL-MOUNDHRI M, 00BRIEN M, SOUBERBIELLE BE: Immunotherapy in lung cancer. Brit. J. Cancer (1998) 78:282–288.
   PubMedGoogle Scholar
• •A nice review on current trends in lung cancer immunotherapy.
   Google Scholar
• HIBI K, LIU Q, BEAUDRY GA et al.: Serial analysis of geneexpression in non-small cell lung cancer. Cancer Res. (1998) 58:5690–5694.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO A, SHIMIZU E, OGURA T, SONE S: Detectionof auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int. J. Cancer (1996) 69:283–289.
   PubMed Web of Science ®Google Scholar
• LENGAUER C, KINZLER KW, VOGELSTEIN B: Genetic instabilities in human cancers. Nature (1998) 396:643–649.
   PubMed Web of Science ®Google Scholar
• GILLILAND LK, WALSH LA, FREWIN MR etal. Elimination of the immunogenicity of therapeutic antibodies. J. Immunol. (1999) 162:3663–3671.
   Google Scholar
• GURE AO, ALTORKI NK, STOCKERT E, SCANLAN MJ, OLD LJ, CHEN YT: Human lung cancer antigens recognized by autologous antibodies: Definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3.D. Cancer Res. (1998) 58:1034–1041.
   PubMed Web of Science ®Google Scholar
• BERGQVIST M, BRATTSTROM D, LARRSON A et al: p53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anti-Cancer Res. (1998) 18:1999–2002.
   PubMed Web of Science ®Google Scholar
• GRAUS F, DALMAU J, RENE R et al.: Anti-hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. j Gun. Oncol (1997) 15:2866–2872.
   Web of Science ®Google Scholar
• KATO M, MOCHIZUKI K, HASHIZUME S et al.: Activity enhancement of a lung cancer-associated human monoclonal antibody 11B4C5 by N-deglycosylation. Hum. Antibod. Hybridomas (1993) 4:9–16.
   PubMedGoogle Scholar
• HARUTA H, TACHIBANA H, MOCHIZUKI K et al.: Class-switching of the IgM type anti-adenocarcinoma human antibody 11B4C5 into an IgG1 type resulted in the loss of the antigen binding ability. Hum. Antibod. (1997) 8:137–144.
   PubMedGoogle Scholar
• MCKNIGHT ME, MUKERJEE S, NASOFF M, GASKINS C, GLASSY MC: Isotype-directed enrichment of B cells by magnetic beads in the generation of immunoreactive human monoclonal antibodies. Hybridoma (1996) 15:255–261.
   PubMed Web of Science ®Google Scholar
• HULS GA, HEIJNEN IAFM, CUOMO ME: A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nature Biotechnol. (1999) 17:276–283.
   PubMed Web of Science ®Google Scholar
• ••A key paper showing the power of antibody libraries.
   Google Scholar
• LARRICK JW: Recombinant antibodies. Human Antibod. Hybridomas (1991) 2: 172–189.
   PubMedGoogle Scholar
• GLASSY MC: Human Monoclonal Antibodies. Overview of methods of production. Chapter 25E:0 In: Protocols in Cell & Tissue Culture. Griffiths JB, Doyle A, Newell DG (Eds.) John Wiley & Sons, London (1993):25E0.1-25E0.4.
   Google Scholar
• HOJO M, MORIMOTO T, MALUCCIO M et al.: Cyclosporin induces cancer progression by a cell-autonomous mechanism. Nature (1999) 397:530–534.
   PubMed Web of Science ®Google Scholar